Registration Form • Apr 26, 2017
Registration Form
Open in ViewerOpens in native device viewer
Lyon, 26th April 2017 - AMOEBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating waterborne bacterial risks announced that its registration document for the 2016 period was submitted to the French Financial Markets Regulator (AMF) on 25th April 2017, recorded as document R.17-023.
The document can be consulted on the company's website www.amoeba-biocide.com. Copies of the registration document are also available at the company's headquarters: 38, avenue des frères Montgolfier, 69680 Chassieu, France.
The registration document includes the following documents:
AMOEBA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.). This entirely natural solution is presented as an alternative to the chemical treatments traditionally used in the industrial sector and complies with the new regulations in terms of chemical emissions into the environment. In a worldwide market for chemical biocides estimated to be worth EUR 21 bn(1), AMOEBA is today concentrating on the segment of industrial air-cooled towers (ACT), estimated to be worth EUR 1.7 bn(2). AMOEBA is continuing with the regulatory procedures necessary to obtain MA for all European countries for the "Air Cooled Towers" application. Based in Lyon-Chassieu (France), AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. For more information: www.amoeba-biocide.com.
(1) : Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets (2) : Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013
Amoéba Nathalie COMBROUSSE Marketing Communication Manager Tel : +33 (0)4 81 09 18 15 [email protected]
Actifin Ghislaine GASPARETTO Communication financière Tel : +33 (0)1 56 88 11 11 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.